|4.||Coronary Artery Disease (Coronary Atherosclerosis)
|1.||Cannon, Christopher P: 136 articles (10/2015 - 02/2002)|
|2.||Braunwald, Eugene: 131 articles (10/2015 - 02/2002)|
|3.||Harrington, Robert A: 111 articles (01/2016 - 01/2002)|
|4.||Wallentin, Lars: 108 articles (10/2015 - 06/2002)|
|5.||Morrow, David A: 103 articles (10/2015 - 02/2002)|
|6.||Murphy, Sabina A: 89 articles (10/2015 - 04/2002)|
|7.||Califf, Robert M: 88 articles (06/2015 - 01/2002)|
|8.||White, Harvey D: 82 articles (01/2016 - 01/2002)|
|9.||Stone, Gregg W: 81 articles (01/2016 - 05/2002)|
|10.||Ohman, E Magnus: 79 articles (10/2015 - 01/2002)|
|1.||clopidogrel (Plavix)FDA Link
01/01/2006 - "Clopidogrel given for up to 1 year in patients undergoing PCI after presentation with acute coronary syndromes is a highly cost-effective treatment strategy."
04/01/2012 - "Based on their beneficial results in comparison to clopidogrel, these agents have found their way into the recent international guidelines for treatment of patients with acute coronary syndromes. "
02/01/2010 - "Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes."
07/01/2010 - "Higher clopidogrel doses have been associated with improved clinical outcomes, especially in those presenting with acute coronary syndrome. "
03/01/2007 - "One-year treatment with clopidogrel is a cost-effective treatment option in patients with acute coronary syndrome from the perspective of a third-party payer in Germany."
|2.||Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
06/01/2013 - "Dual antiplatelet therapy, consisting of aspirin and a P2Y12 receptor inhibitor, has dramatically reduced the incidence of atherothrombotic events for patients with acute coronary syndrome and those undergoing a percutaneous coronary intervention (PCI). "
08/01/2012 - "Our results indicate that PAR antagonists used in combination with aspirin provide a potent yet safe antithrombotic strategy in mice and provide insights into the safety and efficacy of using PAR antagonists for the prevention of acute coronary syndromes in humans."
12/01/2000 - "Other than aspirin, there are few oral antithrombotic treatments with proven efficacy in patients with acute coronary syndrome. "
08/22/2002 - "In patients with acute coronary syndrome, this regimen is superior to monotherapy with acetylsalicylic acid. "
08/01/2014 - "Dual antiplatelet therapy consisting of one of the P2Y12 receptor inhibitors in conjunction with aspirin is the mainstay of treatment for patients with acute coronary syndromes (ACS) and those undergoing percutaneous coronary interventions (PCI). "
09/01/2011 - "Glycoprotein IIb/IIIa antagonists are effective for the treatment of acute coronary syndromes proven in large clinical trials. "
06/01/2004 - "Potent inhibition of the platelet glycoprotein IIb/IIIa receptor has improved the acute outcome of patients presenting with acute coronary syndromes (ACS). "
01/01/1999 - "The results of different clinical studies show evidence that glycoprotein IIb-IIIa antagonists, given intravenously, are effective in the management of acute coronary intervention with high thrombogenic risk, and also help to control the early phase of acute coronary syndromes. "
09/15/2004 - "Although the efficacy of glycoprotein IIb/IIIa inhibition in non-ST-elevation acute coronary syndromes is greatest in patients who undergo percutaneous coronary intervention (PCI), it was hypothesized that high-risk patients managed without PCI also benefit. "
07/11/2000 - "Although intravenous glycoprotein IIb/IIIa inhibitors are beneficial in patients with acute coronary syndromes, prolonged oral IIb/IIIa inhibition might provide an additional reduction in recurrent events. "
|4.||Heparin (Liquaemin)FDA LinkGeneric
08/01/1999 - "In addition, their use in conjunction with ASA and heparin in the acute coronary syndrome led to further significant reduction of cardiovascular events in several studies. "
04/01/2012 - "Low-molecular-weight heparins (LMWHs) have shown equivalent or superior efficacy and safety to unfractionated heparin as antithrombotic therapy for patients with acute coronary syndromes. "
08/01/2008 - "Unfractionated heparin (UFH) is a mainstay of treatment for patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS), but the practice of weight-adjusted bolus and infusion dosing has not been carefully evaluated. "
09/01/2001 - "There is accumulating evidence that LMWHs are safe and effective alternatives to standard heparin for the treatment of acute coronary syndromes and that they offer practical and therapeutic advantages."
02/01/2011 - "Randomized, partially-blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system compared to unfractionated heparin or low molecular heparin in subjects with acute coronary syndrome (RADAR) is designed to assess both the efficacy of the anticoagulant RB006 and the safety of a range of levels of RB006 reversal with RB007. "
02/01/2013 - "This CYP-mediated drug-drug interaction might lead to a significant reduction of prasugrel efficacy in HIV-infected patients with acute coronary syndrome."
02/01/2010 - "These pharmacodynamic properties led prasugrel to be more effective in preventing ischemic events in patients with acute coronary syndromes undergoing PCI in the setting of the recent TRITON-TIMI 38 study. "
11/01/2009 - "The promising results seen with prasugrel in large, randomized trials led to its recent approval by the US Food and Drug Administration for reducing thrombotic cardiovascular events in patients with acute coronary syndromes managed with percutaneous coronary intervention. "
12/01/2009 - "Given the totality of data available, prasugrel appears to be a promising treatment option for patients with acute coronary syndromes who are undergoing percutaneous coronary interventions."
12/01/2013 - "The lack of effect from genetic variants on prasugrel AM generation or antiplatelet activity is consistent with previous studies in healthy volunteers and is consistent with improved efficacy in acute coronary syndrome patients managed with percutaneous coronary intervention. "
|6.||Enoxaparin (Lovenox)FDA LinkGeneric
08/01/2004 - "Enoxaparin seems to offer safe and effective procedural anticoagulation in patients undergoing percutaneous intervention for acute coronary syndromes. "
02/01/2003 - "[The safety and efficacy of pre-treatment with enoxaparin (Clexane) in acute coronary syndrome patients undergoing percutaneous coronary intervention]."
06/01/2008 - "In the treatment of acute coronary syndromes with non-ST-segment elevation enoxaparin was as efficient as UFH, but with a simpler management (SYNERGY and A to Z studies). "
04/01/2005 - "Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial."
04/01/2005 - "Enoxaparin in clinical practice and clinical trials of non-ST-elevation Acute Coronary Syndrome (NSTE-ACS)."
|7.||Platelet Membrane Glycoprotein IIbIBA
02/01/2009 - "The emergency physicians support early identification of high-risk non-ST-elevation acute coronary syndrome patients and early administration of GP IIb-IIIa inhibitors, which are linked to improved patient outcomes. "
03/01/2000 - "These GP IIb/IIIa antagonists have been shown to be effective in improving outcomes among patients undergoing percutaneous coronary interventions and for the treatment of acute coronary syndromes. "
05/01/1997 - "[Inhibitors of platelet receptors GP IIB/IIIA: a new therapeutic class and its promise in the treatment of acute coronary syndromes]."
02/12/1999 - "The clinical efficacy of GP IIb/IIIa-antagonists for acute percutaneous coronary interventions and in the management of the acute coronary syndrome is established. "
01/01/2008 - "Based on clinical trials, GP IIb/IIIa receptor antagonists have been extensively studied and used in patients with acute coronary syndrome or during percutaneous coronary interventions. "
|8.||eptifibatide (Integrilin)FDA Link
09/01/2013 - "Consistent with previous literature, upstream treatment with eptifibatide was associated with improved outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients treated with PCI; however, a nonsignificant interaction term precludes a definite conclusion."
01/01/2006 - "Data from large clinical trials indicate that intravenous eptifibatide as adjunctive therapy to standard care is effective in patients with non-ST-segment elevation (NSTE) acute coronary syndromes (ACS) and/or undergoing percutaneous coronary intervention (PCI). "
01/01/2005 - "Data from large clinical trials indicate that intravenous eptifibatide as adjunctive therapy to standard care is effective in patients with non-ST-segment elevation (NSTE) acute coronary syndromes (ACS) and/or undergoing percutaneous coronary intervention (PCI). "
11/01/2007 - "The alphaIIbbeta3 antagonist eptifibatide is an effective treatment for patients with acute coronary syndromes (ACS). "
09/01/2000 - "PURSUIT was a double-blind, randomized trial that examined the efficacy of eptifibatide (180 microg/kg bolus + continuous infusion of 2.0 microg/kg/min for < or =96 h) versus placebo among patients who had acute coronary syndromes but not persistent ST-segment elevation. "
|9.||bivalirudin (Angiomax)FDA Link
08/01/2009 - "The objective was to assess the safety and efficacy of bivalirudin monotherapy in patients with high-risk acute coronary syndrome (ACS) presenting to the emergency department (ED). "
01/01/2008 - "In summary, is has been shown that bivalirudin alone is safe and effective in the vast majority of patients suffering from acute coronary syndromes and being treated invasively. "
01/01/2012 - "Randomized trials show improved outcomes among acute coronary syndrome patients treated with bivalirudin. "
01/01/2008 - "Recent trials (ACUITY and HORIZONS studies) added evidence regarding safety and efficacy of bivalirudin use in acute coronary syndromes. "
01/01/2008 - "Safety and efficacy of bivalirudin in acute coronary syndromes."
|10.||tirofiban (Aggrastat)FDA Link
09/01/2009 - "To evaluate the safety and efficacy of tirofiban in high risk patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) after percutaneous coronary intervention (PCI). "
12/01/2011 - "[Tirofiban improved the prognosis of senior acute coronary syndrome patients received percutaneous coronary intervention]."
10/01/2008 - "To investigate the efficacy of intracoronary tirofiban during primary percutaneous coronary intervention (PCI) for patients with acute coronary syndrome (ACS). "
04/01/2007 - "Evaluation on the safety and efficacy of tirofiban in the treatment of acute coronary syndrome."
01/01/2015 - "Efficacy and Safety of Intracoronary versus Intravenous Administration of Tirofiban during Percutaneous Coronary Intervention for Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials."
01/01/2003 - "Interventional methods, most of all stent implantation, seem to be the best treatment of 5-FU-related acute coronary syndromes."
08/01/2012 - "We evaluated the safety and efficacy of drug-eluting coronary stents (DES) compared with bare-metal stents (BMS) for Medicare beneficiaries with acute coronary syndromes using the rapid uptake of DES in clinical practice as an instrument. "
03/01/2015 - "We compared efficacy of bare-metal stent (BMS) and drug-eluting balloon (DEB) combination vs BMS alone, in patients with non-ST elevation acute coronary syndrome treated with percutaneous coronary intervention (PCI). "
08/01/2015 - "Impact of coronary artery stent edge dissections on long-term clinical outcome in patients with acute coronary syndrome: an optical coherence tomography study."
07/01/2015 - "Use of drug-eluting versus bare-metal stents after an acute coronary syndrome in Portugal: the EURHOBOP study."
|2.||Angioplasty (Angioplasty, Transluminal)
01/01/2013 - "Acute coronary syndrome in a 100-year-old woman treated successfully with primary percutaneous coronary angioplasty."
01/01/2012 - "Primary coronary angioplasty with stenting is a safe effective treatment for acute coronary syndrome in this category of patients."
07/01/1997 - "These agents show great promise in reducing ischaemic complications of coronary angioplasty and acute coronary syndromes. "
08/01/2014 - "To date, no randomized study has investigated the value of optical coherence tomography (OCT) in optimizing the results of coronary angioplasty for non-ST-segment elevation acute coronary syndromes. "
04/06/2010 - "The aim of this study was to determine the impact of delay to angioplasty in patients with acute coronary syndromes (ACS). "
04/01/2012 - "Quality of life of acute coronary syndrome patients is significantly improved at 6 months after drug-eluting stents implantation. "
07/01/2014 - "Safety and efficacy of first-generation and second-generation drug-eluting stents in the setting of acute coronary syndromes."
12/01/2014 - "Drug-eluting stent implantation in patients with acute coronary syndrome - the Activity of Platelets after Inhibition and Cardiovascular Events: Optical Coherence Tomography (APICE OCT) study."
07/01/2014 - "Type 2 diabetic patients (100) with non-ST-elevation acute coronary syndrome who underwent PCI and Xience V drug-eluting stent implantation were included in this study. "
05/01/2014 - "Differential healing response attributed to culprit lesions of patients with acute coronary syndromes and stable coronary artery after implantation of drug-eluting stents: an optical coherence tomography study."
|4.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)
09/01/2007 - "In the present study, the efficacy of the therapy during emergent coronary artery bypass grafting (CABG) for acute coronary syndrome (ACS) is investigated. "
09/01/2007 - "Efficacy of continuous low-dose hANP administration in patients undergoing emergent coronary artery bypass grafting for acute coronary syndrome."
12/01/2015 - "Conduct a meta-analysis to study the prognostic influence of a previous coronary artery bypass grafting (CABG) in patients admitted for an acute coronary syndrome (ACS). "
11/01/2015 - "The study population consisted of 1314 patients aged >30 years (64.7 ± 10.6 years, 1051 male) with CAD who were hospitalized for acute coronary syndrome or coronary artery bypass grafting. "
10/01/2015 - "Coronary Artery Bypass Surgery Compared With Percutaneous Coronary Intervention for Proximal Left Anterior Descending Artery Treatment in Patients With Acute Coronary Syndrome: Analysis From the ACUITY Trial."
06/01/2011 - "This study sought to assess, with optical coherence tomography (OCT), presumably culprit atherosclerotic lesions of saphenous vein grafts (SVGs) in patients with acute coronary syndromes (ACS). "
10/01/2010 - "Clinical outcomes in patients with acute coronary syndromes randomized in the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial who underwent percutaneous coronary intervention (PCI) of saphenous vein grafts (SVGs) were examined. "
06/01/2015 - "A Rare Case of Spontaneous Dissection in a Left Internal Mammary Artery Bypass Graft in Acute Coronary Syndrome."
03/01/2015 - "EPDs were used in 21.2% of saphenous vein grafts (median age, 75; 23% women) and were more common in acute coronary syndrome (versus non-acute coronary syndrome; 22% versus 19%), de novo (versus restenotic; 22% versus 14%), and graft body lesions (versus aortic and distal anastomosis; 24% versus 20% versus 8%, respectively). "
03/01/2015 - "Prespecified high-risk subgroups included acute coronary syndrome and de novo or graft body lesions. "